Calithera Biosciences, Inc. (NASDAQ:CALA) Files An 8-K Results of Operations and Financial Condition

Calithera Biosciences, Inc. (NASDAQ:CALA) Files An 8-K Results of Operations and Financial Condition

Story continues below


Results of Operations and Financial

On May9, 2017, Calithera Biosciences, Inc. issued a press release
announcing its financial results for the quarter and year ended
March31, 2017. A copy of this press release is attached hereto as
Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the
information in this Current Report on Form 8-K, including Exhibit
99.1, shall not be deemed filed for purposes of Section18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liability of that section, nor shall
it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, whether
made before or after the date hereof, except as expressly set
forth by specific reference in such filing to this Current Report
on Form 8-K.

Item9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.


99.1 Press Release, dated May9, 2017

About Calithera Biosciences, Inc. (NASDAQ:CALA)

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. Its lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, which is an enzyme that depletes the amino acid arginine, a key metabolic nutrient for T-cells. Its lead preclinical program in tumor immunology is directed at developing inhibitors of the enzyme arginase and may provide a therapeutic agent for the target. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. Hexokinase is an enzyme in the pathway that allows cancer cells to convert glucose to energy to fuel cancer cell growth.

Calithera Biosciences, Inc. (NASDAQ:CALA) Recent Trading Information

Calithera Biosciences, Inc. (NASDAQ:CALA) closed its last trading session up +0.40 at 11.30 with 374,977 shares trading hands.

An ad to help with our costs